{"organizations": [], "uuid": "dfb7c0c2276432cd1783614a07cfc1ddcb5a646d", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-array-biopharma-says-its-partner-s/brief-array-biopharma-says-its-partner-seeks-withdrawal-of-marketing-authorization-applications-for-binimetinib-monotherapy-in-eu-switzerland-and-australia-idUSFWN1PI1BQ", "country": "US", "domain_rank": 408, "title": "BRIEF-Array Biopharma Says Its partner Seeks Withdrawal of Marketing Authorization Applications For Binimetinib Monotherapy in EU, Switzerland And Australia", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-24T01:01:00.000+02:00", "replies_count": 0, "uuid": "dfb7c0c2276432cd1783614a07cfc1ddcb5a646d"}, "author": "", "url": "https://www.reuters.com/article/brief-array-biopharma-says-its-partner-s/brief-array-biopharma-says-its-partner-seeks-withdrawal-of-marketing-authorization-applications-for-binimetinib-monotherapy-in-eu-switzerland-and-australia-idUSFWN1PI1BQ", "ord_in_thread": 0, "title": "BRIEF-Array Biopharma Says Its partner Seeks Withdrawal of Marketing Authorization Applications For Binimetinib Monotherapy in EU, Switzerland And Australia", "locations": [], "entities": {"persons": [{"name": "fabre", "sentiment": "none"}, {"name": "pierre fabre", "sentiment": "none"}], "locations": [{"name": "australia", "sentiment": "none"}, {"name": "switzerland", "sentiment": "none"}, {"name": "australia", "sentiment": "none"}, {"name": "switzerland", "sentiment": "none"}], "organizations": [{"name": "eu", "sentiment": "neutral"}, {"name": "australia reuters", "sentiment": "none"}, {"name": "biopharma inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 23 (Reuters) - Array Biopharma Inc:\n* ARRAY BIOPHARMA SAYS PIERRE FABRE MEDICAMENT, REQUESTED THAT MARKETING AUTHORIZATION APPLICATIONS FOR BINIMETINIB MONOTHERAPY BE WITHDRAWN\n* ARRAY BIOPHARMA - WITHDRAWAL OF MAA APPLICATIONS FOR BINIMETINIB MONOTHERAPY IN NRAS-MUTANT MELANOMA REQUESTED IN EU, SWITZERLAND AND AUSTRALIA\n* ARRAY BIOPHARMA - PIERRE FABRE MEDICAMENT IS ARRAY'S COLLABORATION PARTNER Source text: ( bit.ly/2DGm2Ug ) Further company coverage:\n ", "external_links": [], "published": "2018-01-24T01:01:00.000+02:00", "crawled": "2018-01-24T01:16:07.032+02:00", "highlightTitle": ""}